Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL157514 | 0.81 | HPGD (0.41) | ALDH1A1HPGDKMT2AL3MBTL1 | |
| SCHEMBL8601696 | 0.80 | RAB9A (0.44) | MAPTHPGD | |
| SCHEMBL8488417 | 0.78 | ALDH1A1 (0.31) | ALDH1A1MAPTHSP90AA1 | |
| SCHEMBL27910084 | 0.78 | ALDH1A1 (0.31) | ALDH1A1MAPTHSP90AA1 | |
| SCHEMBL7400361 | 0.77 | NPC1 (0.33) | ALDH1A1MAPT | |
| SCHEMBL28401610 | 0.75 | LMNA (0.35) | MAPTMEN1HPGDKMT2A | |
| SCHEMBL28864489 | 0.74 | — | — | |
| SCHEMBL8639915 | 0.72 | ALDH1A1 (0.39) | ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL305025 | 0.70 | ALDH1A1 (0.40) | ALDH1A1MEN1HPGDKMT2A | |
| SCHEMBL9652775 | 0.68 | ALDH1A1 (0.35) | ALDH1A1MEN1HPGDKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844010-B1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA AS (DK) | 2013-02-13 | — | — | EP | claimed |
| EP-1844010-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-10-17 | — | — | EP | claimed |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | LEO PHARMA A/S (DK) | 2007-09-20 | — | — | US | claimed |
| WO-2007082533-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-07-26 | — | — | WO | claimed |
| US-12637417-B2 | Method for producing 2-(halogenated methyl)naphthalene and 2-naphthyl acetonitrile | UBE CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| US-20240109840-A1 | METHOD FOR PRODUCING 2-(HALOGENATED METHYL)NAPHTHALENE AND 2-NAPHTHYL ACETONITRILE | API CORPORATION (JP) | 2024-04-04 | — | — | US | disclosed |
| EP-4174049-A1 | METHOD FOR PRODUCING 2-(HALOGENATED METHYL)NAPHTHALENE AND 2-NAPHTHYL ACETONITRILE | API Corporation (JP) | 2023-05-03 | — | — | EP | disclosed |
| EP-1844010-B1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA AS (DK) | 2013-02-13 | — | — | EP | disclosed |
| EP-1844010-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-10-17 | — | — | EP | disclosed |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | LEO PHARMA A/S (DK) | 2007-09-20 | — | — | US | disclosed |
| WO-2007082533-A1 | ISOMERISATION OF PHARMACEUTICAL INTERMEDIATES | LEO PHARMA A/S (DK) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637417-B2 | Method for producing 2-(halogenated methyl)naphthalene and 2-naphthyl acetonitrile | CYP1A1, NAT1, CYP1A2 | ALDH1A1 640/4885MAPT 1202/4885HSP90AA1 3855/4885 |
| US-20240109840-A1 | METHOD FOR PRODUCING 2-(HALOGENATED METHYL)NAPHTHALENE AND 2-NAPHTHYL ACETONITRILE | CYP1A1, CYP2E1, NPM1 | ALDH1A1 1386/4885MAPT 3000/4885HSP90AA1 3199/4885 |
| US-20070215455-A1 | Isomerisation of pharmaceutical intermediates | CYP24A1, CYP2R1, VDR | ALDH1A1 532/4885MAPT 3554/4885HSP90AA1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.